openPR Logo
Press release

Proteros enters into a research agreement for structure based lead generation

09-28-2010 09:26 AM CET | Health & Medicine

Press release from: Proteros biostructures GmbH

Martinsried, Germany, September 27th, 2010. Proteros biostructures GmbH (Proteros) announced today that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), under which Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD. Under the agreement, Proteros will deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and fragment library, compound profiling, and medicinal chemistry activities aimed at rapid fragment evolution and lead finding.

Torsten Neuefeind, Chief Executive Officer for Proteros, stated that “this partnership will build on a long standing and successful relationship.”

About Proteros biostructures GmbH:
Proteros is a privately held company which provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 60 pharmaceutical and biotechnology clients in North America, Europe and Japan.

Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 – 0
E-Mail: herrenknecht@proteros.com
Internet: www.proteros.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros enters into a research agreement for structure based lead generation here

News-ID: 145939 • Views: 1312

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Martinsried

MiC – the first Wiki for Dynamic Systems; Wiki and Simulation-Models - Interac …
Martinsried / Munich, July 23 2012: Dynamic systems can be found everywhere in our environment, since every process has a certain dynamic that can be determined and described. May be the car driving uphill, or the tank getting filled with some liquid – by using the interactive Wiki called MiC, engineers and students can explore which information is required to describe dynamic systems. The approach of providing an interactive Wiki is
Proteros has relocated to a tailor-made facility in Martinsried
Martinsried, October 24th 2011. Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany. After a two-year planning period, Proteros has reached an important milestone in its development by centralizing all operations within a purpose-built facility. The 4,000 square-meter of laboratory and office space, worth a total of about 15 M €, has been optimally designed
Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsr …
Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology. Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery. Dr.
World’s First Autonomous Plug&Play Feedback Controller „RTAC“ from ExpertC …
Martinsried / Munich, Germany, March 2, 2010: The CAE software developer ExpertControl further extends its head start in feedback control for the broad automation market again. The software tools ecICP and ecCST already offer capabilities which eclipse other control design utilities. With the autonomous plug&play feedback controller RTAC (Realtime Adaptive/Automatic Control), ExpertControl takes one more step forward and combines fully automatic control design, parameter tuning and data acquisition within one
Fully automated Design of Position Control for Robots with eliminated Output Osc …
Martinsried / Munich, Germany, June 29 2009 - With ecICP, ExpertControl now offers for the robot industry a software tool to gain substantial quality increase in terms of position control even when no sensors are used to detect the output position oscillations. The new capabilities of ecICP factor this missing oscillation information in, help to increase SCARA robots’ accuracy and provide at the same time both optimal setpoint behavior and
ecSTYLE - Style Guide Checker - Checking of Modeling Guide Lines for Simulink Mo …
Martinsried/Munich, Germany, April 20 2009: ExpertControl announce ecSTYLE, a flexible software package for checking Simulink models if they conform to programming style guides such as the MAAB style guide. Automatic corrections are supported as well.. In model-based design, The MathWorks, Inc Simulink® software is widely used. Models are often developed in teamwork, therefore it is important that all participants follow given guidelines to avoid misunderstandings and increase the readability and